Immuno Vaccine Inc (IMMVF) 0.4468 $IMMVF Immunovaccine

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Immuno Vaccine Inc (IMMVF) 0.4468 $IMMVF

Immunovaccine Provides Corporate Update and Announces Second Quarter 2016 Financial Results
Marketwired - Tue Aug 09, 4:06PM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - Aug 9, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "Company" (TSX:IMV)(OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today provided a corporate update and announced financial results for the second quarter ended June 30, 2016.
IMV.TO: 0.58 (unch)

Immunovaccine Announces Preclinical Collaboration for DepoVax(TM)-Based Malaria Vaccine
Marketwire Canada - Thu Jun 02, 6:06AM CDT
Initial Study Conducted With The University of Edinburgh to Examine Vaccine Candidate's Effects on Malaria Parasites Linked to Most Severe Form of the Disease
IMV.TO: 0.58 (unch)

Immunovaccine Announces Financial Results for Quarter Ended March 31, 2016
Marketwire Canada - Tue May 10, 4:06PM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 10, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "Company" (TSX:IMV) (OTCQX:IMMVF), a clinical-stage vaccine and immunotherapy company, today released its financial and operational results for the first quarter ended March 31, 2016.
IMV.TO: 0.58 (unch), INCY: 81.98 (+5.87), LDOS: 40.35 (+0.86)

Immunovaccine Launches DPX-NEO Program to Develop Patient-Specific Neoepitope Immunotherapies
Marketwired - Thu May 05, 6:06AM CDT
HALIFAX, NOVA SCOTIA--(Marketwired - May 5, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, today announced the launch of its DPX-NEO program to develop neoepitope immunotherapies to further expand the immuno-oncology applications for its DepoVax™-based vaccines. As its first official partnership for this program, Immunovaccine will collaborate with experts in this field at UConn Health on a preclinical study to evaluate the immunologic and anti-tumor activity of patient-specific neoepitopes.
IMV.TO: 0.58 (unch)

Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
Marketwired - Thu Apr 28, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that Chief Executive Officer Frederic Ors will present an update on the Company's recent progress and future strategy at the 2016 Bloom Burton & Co. Healthcare Investor Conference at the Sheraton Centre Toronto Hotel on Tuesday, May 3, 2016 at 3:00 p.m. Eastern Time.
IMV.TO: 0.58 (unch)

New Preclinical Study Shows Immunovaccine's DepoVax(TM)-Based Cancer Vaccine May Improve Efficacy of Checkpoint Inhibitors
Marketwired - Wed Apr 20, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, presented new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016. The investigators' findings showed that a combination immunotherapy using a DepoVax(TM)-based vaccine could enhance the anti-tumor effects of a PD-1 blockade, controlling growth in advanced HPV-expressing tumors in animal models.
IMV.TO: 0.58 (unch)

Immunovaccine Elects Medicago CEO Andy Sheldon as Board Chairman; Reports Results of the Annual General Meeting (AGM)
Marketwired - Fri Apr 15, 6:06AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV) (OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today elected Andrew Sheldon as chairman of its board of directors. Mr. Sheldon, who currently serves as President and CEO of Medicago, joined the board after the company's annual and special meeting of shareholders. Newly named Chief Executive Officer Frederic Ors was also elected to the board.
IMV.TO: 0.58 (unch)

Immunovaccine Names Frederic Ors Chief Executive Officer; Andy Sheldon, Medicago CEO, to Join Board of Directors
Marketwired - Wed Apr 13, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced that Frederic Ors has been appointed Chief Executive Officer. He and Andy Sheldon, President and CEO of Medicago, will be nominated to the board of directors at the Company's AGM on April 14, and the Board will recommend their election.
IMV.TO: 0.58 (unch)

Immunovaccine to Present New Pre-Clinical Data at the 2016 AACR Annual Meeting
Marketwired - Mon Apr 11, 4:05PM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, announced that new pre-clinical data on DPX(TM)-based cancer vaccines will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, which be held in New Orleans, Louisiana, April 16-20, 2016.
IMV.TO: 0.58 (unch)

Immunovaccine and Leidos Join Forces to Develop a Zika Virus Vaccine Candidate
Marketwired - Thu Apr 07, 6:05AM CDT
Immunovaccine Inc. ("Immunovaccine" or the "company" (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, and Leidos (NYSE: LDOS), a health, national security and infrastructure solutions company, today announced they will collaborate on developing a vaccine against the mosquito-borne Zika virus and infection, which may be linked to neurological birth defects.
IMV.TO: 0.58 (unch), LDOS: 40.35 (+0.86)

Immunovaccine Announces 2015 Year-End Results
Marketwired - Tue Mar 29, 4:06PM CDT
Immunovaccine Inc. (TSX: IMV)(OTCQX: IMMVF), a clinical stage vaccine and immunotherapy company, today announced its financial and operational results for the year ended December 31, 2015.
IMV.TO: 0.58 (unch), INCY: 81.98 (+5.87)

Pipeline of Genital Herpes Market Covering 19 Companies and 17 Drug Profiles
PR Newswire - Thu Mar 24, 1:00AM CDT
New market research report titled "Genital Herpes - Pipeline Review, H2 2015" enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
IMDZ: 7.07 (+0.23), FOMX: 8.80 (+0.10), GNCA: 5.24 (+0.06), NNVC: 1.65 (-0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 70

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Gaotu Techedu's Q3 Results: A Look at AI-Driven Growth

Updated Category News Views 11

Gaotu Techedu to Unveil Q3 Results Mark your calendars, folks—Gaotu Techedu Inc. (NYSE: GOTU) is gearing up to dish out its third quarter financial results on November 25, 2026. As usual, these numbers will slide out before the U.S. markets spring into action. It's one of those moments when investors like us strap in and watch for any movement that might toss our...

Continue Reading
Horizon Capital Hits €200M for Ukraine Resilience

Updated Category News Views 30

An Unprecedented Leap Amidst Uncertainty Right in the middle of rebuilding a nation, Horizon Capital's Catalyst Fund has managed to tap into a well of optimism—or guts, depending on how you look at it. With €200 million already in its pocket out of a €300 million goal, this private equity powerhouse is taking a calculated gamble on Ukraine's economic resilience and...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 165

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 121

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 39

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 275

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading

Top 5 Most Recently Viewed Articles

Matt Hougan Shares Insights on Bitcoin's Potential Surge

Updated Category News Views 165

Understanding Bitcoin's Growth Potential Matt Hougan, the Chief Investment Officer at Bitwise, sheds light on the driving forces behind the burgeoning interest in Bitcoin. He emphasizes concerns over the decline of fiat currencies and noteworthy inflows into Bitcoin ETFs as the catalysts propelling Bitcoin's journey towards new heights. This surge towards potential record...

Continue Reading
Empowering Futures: Access Bank's Commitment to Education

Updated Category News Views 174

Support for Educational Development In recent years, The Access Bank UK Ltd has made significant strides in supporting educational initiatives aimed at transforming lives. This commitment is exemplified by the annual Polo Cup event that they host in collaboration with UNICEF and Fifth Chukker. The Access Bank Cup has become more than just a sporting affair; it is a beacon...

Continue Reading
Gary Brecka's Event Redefines Longevity's Future in L.A.

Updated Category News Views 46

Exploring Longevity: A Day Like No Other Alright, picture this: a convergence of wellness diehards, human performance buffs, and curious minds, all filing into the Peacock Theater in Los Angeles. It's August 16th and they're here for Gary Brecka LIVE. This is no run-of-the-mill wellness seminar; it's an exclusive deep dive into the world of longevity hosted by Sequel...

Continue Reading
Ultragenyx Pharmaceutical and Others Face Challenges in Ratings

Updated Category News Views 164

Stock Market Overview This morning, U.S. stock futures indicated a downward trend, with the Dow futures decreasing by about 100 points. Given the numerous fluctuations in the market recently, this drop is indicative of the challenges many companies are facing. Ultragenyx Pharmaceutical Inc Performance Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have sharply...

Continue Reading
Netflix's Future: Overcoming Slower Subscriber Growth Strategies

Updated Category News Views 185

Analyzing Netflix's Subscription Growth and Future Strategies Netflix, a leading name in streaming services, is facing a potential slowdown in subscriber additions. Analysts suggest that the streaming giant might experience its most modest subscriber growth in the past six quarters as the gains from its recent password-sharing crackdown start to wane. With this shifting...

Continue Reading